GSK4429016 / LimmaTech Biologics, GSK - LARVOL DELTA

Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A first time in human phase I/II randomised and controlled study. (PubMed, J Infect Dis) - P1/2 | "Kleb4V is the first K. pneumoniae conjugate vaccine candidate to reach clinical assessment. The Kleb4V bioconjugate was immunogenic, well tolerated and with an acceptable safety profile in the target population of adults aged 55-70 years for all 4 vaccine-serotypes."

Journal • P1/2 data • Infectious Disease • Pneumonia

SAFETY AND IMMUNOGENICITY OF A KLEBSIELLA PNEUMONIAE TETRAVALENT BIOCONJUGATE VACCINE (KLEB4V) ADMINISTERED TO HEALTHY ADULTS: A FIRST IN HUMAN PHASE I/II RANDOMIZED AND CONTROLLED STUDY (ISPPD 2024) - "Conclusions Kleb4V bioconjugate was immunogenic for all 4 vaccine-serotypes in the target population of adults aged 55-70 years old. Significant increase in IgG titers 2 weeks after 1st vaccination for all serotypes was observed persisting until the last visit 8 months following 1st vaccination."

Clinical • P1/2 data • Infectious Disease • Pneumococcal Infections • Pneumonia • Septic Shock

Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) (clinicaltrials.gov) - P1/2 | N=166 | Completed | Sponsor: LimmaTech Biologics AG | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumonia

Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) (clinicaltrials.gov) - P1/2 | N=166 | Active, not recruiting | Sponsor: LimmaTech Biologics AG | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2022 ➔ Sep 2022 | Trial primary completion date: Jun 2022 ➔ Sep 2022

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Pneumonia